Visudyne, Triamcinolone Acetonide, Lucentis in Wet Age-Related Macular Degeneration

VITAL

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-08000175

Enrollment

Unknown

Registered

2008-11-09

Start date

2007-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal neovascularization, Age-related macular degeneration.

Interventions

PDT-V 25 J/cm2 300 mW:Intravitreal ranibizumab 0.5 mg, juxtascleral triamcinolone acetonide 40 mg, verteporfin with reduced fluence and reduced irradiance PDT (25 J/cm2, 300 mW)

PDT-V 25 J/cm2 600 mW:Intravitreal ranibizumab 0.5 mg, juxtascleral triamcinolone acetonide 40 mg, verteporfin with reduced fluence and standard irradiance PDT (25 J/cm2, 600 mW)

PDT-V 50 J/cm2 600 mW:Intravitreal ranibizumab 0.5 mg, juxtascleral triamcinolone acetonide 40 mg, verteporfin with standard fluence and standard irradiance PDT (50 J/cm2, 600 mW)

Eligibility

Sex/Gender

Male

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Signed informed consent form, subfoveal choroidal neovascularization due to age-related macular degeneration.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Number of retreatments;Visual acuit;	—

Secondary

Measure	Time frame
Safety;Retinal angiography and OCT.;Visual acuity;	—

Countries

Italy

Contacts

Public ContactProf. Paolo Lanzetta

verittidaniele@gmail.com+39 0432 559907

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026